These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1693997)

  • 1. Aprotinin for bleeding after cardiopulmonary bypass.
    Bidstrup B
    Lancet; 1990 Jun; 335(8704):1535-6. PubMed ID: 1693997
    [No Abstract]   [Full Text] [Related]  

  • 2. Unorthodox use of aprotinin to control life-threatening bleeding after cardiopulmonary bypass.
    Angelini GD; Cooper GJ; Lamarra M; Bryan AJ
    Lancet; 1990 Mar; 335(8692):799-800. PubMed ID: 1690831
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.
    Blauhut B; Gross C; Necek S; Doran JE; Späth P; Lundsgaard-Hansen P
    J Thorac Cardiovasc Surg; 1991 Jun; 101(6):958-67. PubMed ID: 1710008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
    Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
    Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass.
    Khalil PN; Ismail M; Kalmar P; von Knobelsdorff G; Marx G
    Thromb Haemost; 2004 Sep; 92(3):568-74. PubMed ID: 15351853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass.
    Spannagl M; Dooijewaard G; Dietrich W; Kluft C
    Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invited letter concerning: topical aprotinin.
    Edmunds LH
    J Thorac Cardiovasc Surg; 1995 Feb; 109(2):400-2. PubMed ID: 7531800
    [No Abstract]   [Full Text] [Related]  

  • 9. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
    Ray MJ; Marsh NA
    Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited letter concerning: aprotinin.
    Edmunds LH; Niewiarowski S; Colman RW
    J Thorac Cardiovasc Surg; 1991 Jun; 101(6):1103-4. PubMed ID: 1710007
    [No Abstract]   [Full Text] [Related]  

  • 11. High or low hematocrits during cardiopulmonary bypass for patients undergoing coronary artery bypass graft surgery? An evidence-based approach to the question.
    Groom RC
    Perfusion; 2001 Sep; 16(5):339-43. PubMed ID: 11565888
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass.
    Vandenvelde C; Fondu P; Dubois-Primo J
    Lancet; 1991 May; 337(8750):1157-8. PubMed ID: 1709248
    [No Abstract]   [Full Text] [Related]  

  • 13. Invited letter concerning: aprotinin use in pediatric cardiac operations.
    Edmunds LH
    J Thorac Cardiovasc Surg; 1993 Apr; 105(4):757-60. PubMed ID: 7682269
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose and high-dose aprotinin improve hemostasis in coronary operations.
    Speekenbrink RG; Wildevuur CR; Sturk A; Eijsman L
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):523-30. PubMed ID: 8751522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aprotinin in cardiac surgery.
    Paolo V; Piero C; Carmine S
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):181. PubMed ID: 7686596
    [No Abstract]   [Full Text] [Related]  

  • 16. Suction, salvage, sutures, and potions: blood management post-aprotinin.
    Baker RA
    Semin Cardiothorac Vasc Anesth; 2009 Jun; 13(2):122-6. PubMed ID: 19617252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The haemostatic response to surgery and trauma.
    Murphy WG; Davies MJ; Eduardo A
    Br J Anaesth; 1993 Feb; 70(2):205-13. PubMed ID: 7679584
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors that influence early extubation: bleeding.
    Ammar T; Silvay G
    J Cardiothorac Vasc Anesth; 1998 Dec; 12(6 Suppl 2):28-9; discussion 41-4. PubMed ID: 9919464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study.
    Mohr R; Goor DA; Lusky A; Lavee J
    Circulation; 1992 Nov; 86(5 Suppl):II405-9. PubMed ID: 1385010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.